1. Response to and Survival after First-Line FOLFIRINOX or Gemcitabine/Nab-Paclitaxel for Localized Pancreatic Ductal Adenocarcinoma. (2021) Authors: Perri, G.; Prakash, L.; Varadhachary, G.R.; Koay, E.J.; Kim, M.; Ikoma, N.; Tzeng, C.; Lee, J.E.; Katz, M.H. Journal: HPB Issue: Volume 23(2021)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗